The U.S. Food and Drug Administration (FDA) granted initial approval to Exdensur (depemokimab) on 2025-12-16. This approval designates depemokimab as a Type 1 - New Molecular Entity, signifying it contains an active ingredient not previously approved by the FDA. The drug is sponsored by GLAXOSMITHKLINE LLC.
Background
Depemokimab, known by its brand name Exdensur, has received the FDA classification of a Type 1 - New Molecular Entity. This designation is given to drugs that contain an active ingredient that has never before been marketed in the United States. Such approvals are significant as they introduce entirely new chemical structures or biological substances into the therapeutic arsenal, often representing advancements in medical treatment.
What this means
The initial FDA approval of Exdensur (depemokimab) as a New Molecular Entity represents a key development in the pharmaceutical landscape. This milestone indicates that the drug has successfully navigated the comprehensive regulatory review process, demonstrating its safety and effectiveness to the FDA for its specific approved indication. For clinicians and patients, the introduction of a Type 1 - New Molecular Entity often means a novel treatment option, potentially addressing unmet medical needs or offering an alternative where existing therapies may be insufficient. Its approval provides a new tool for healthcare providers to consider in their treatment strategies.
Source
The information regarding the initial FDA approval of Exdensur (depemokimab) was obtained from the U.S. Food and Drug Administration (FDA) on 2025-12-16. This approval is officially documented on the accessdata.fda.gov website, which serves as a primary source for FDA regulatory actions.